PV Bulletin

Regulatory intelligence & pharmacovigilance updates, mapped to your role.

Drug safety and regulatory intelligence for QPPV, Signal, Labeling, PV Ops, and Device Vigilance — daily briefings with operational next steps.

Latest intelligence

publicEMA · European Union · Updated Sep 7, 2026

Co-ordinating good manufacturing practice (GMP) inspections for centrally authorised products

Urgency: High

Ensure all sites listed in marketing authorization applications are ready for inspection upon submission, and adhere to the new timelines for inspection requests and report submissions.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Latest
Read impact briefarrow_forward
publicTGA · Australia · Updated Sep 7, 2026

Deep Heat Extra Strength 100g Cream

Urgency: High

Regulatory Intelligence teams must initiate checks to monitor compliance and management of this recall, ensuring affected lots are removed from distribution.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Sep 4, 2026

New EU supply chain to end Visudyne shortage

Urgency: High

Monitor the supply chain developments and prepare to adjust inventory management practices as the end of the shortage approaches.

Signal ManagementSignal Management Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Signal Management Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Sep 4, 2026Translated From French

Parenteral iron-containing medicinal products - referral

Urgency: High

Monitor for changes in labeling requirements and risk management strategies as a result of the ongoing review by PRAC.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Sep 4, 2026Translated From French

PRAC 3 September 2026: Starts safety review of injectable iron-containing medicines Image credit: © tadamichi | stock.adobe.com Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 31 August - 3 September 2026 4 September 20

Urgency: High

Signal management teams need to prepare for potential updates in labeling, usage guidelines, and monitoring requirements for injectable iron-containing medicines.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency · European Union · Updated Sep 4, 2026

Dengue Tetravalent Vaccine (Live, Attenuated) Takeda - opinion on medicine for use outside EU

Urgency: High

Regulatory compliance workflows involving the Dengue Tetravalent Vaccine outside the EU need to incorporate the EMA's positive opinion concerning its use in individuals aged 4 to 60.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEMA · European Union · Updated Sep 4, 2026Translated From French

PSUSA/00001345/202512 - periodic safety update report single assessment

Urgency: High

Regulatory intelligence processes must update reporting timelines and workflows to incorporate the new PSUSA findings for exemestane.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Sep 4, 2026

Targeted Signal Management (TSM) for Phenobarbital in Cats and Dogs

Urgency: High

MAHs of products containing phenobarbital must monitor new cases of AHS and submit yearly updates to IRIS. The annual statement submission deadline is set for the end of November each year.

Signal ManagementSignal Management Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Signal Management Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward